C4 Therapeutics Inc (CCCC)
C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies designed to degrade disease-causing proteins. Its lead candidate, Cemsidomide, is an orally available monodac intended to target IKZF1 and IKZF3 for use across multiple lines of therapy in multiple myeloma, and it has completed phase 1 testing. The company is also advancing CFT8919, an orally available allosteric bidac degrader directed at mutant epidermal growth factor receptor in non-small cell lung cancer, including the L858R mutation. In addition, C4 Therapeutics is working on degraders for inflammation, neuroinflammation, and neurodegeneration. The company has collaboration agreements with F. Hoffmann-La Roche Ltd, Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., Merck KGaA, and Roche Holding AG for degrader-antibody conjugate development in cancer. Founded in 2015, it is headquartered in Watertown, Massachusetts.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-CCCC
|
$3.92
|
2.0% Upside
|
Fair
|
$13.33
|
247.2% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-4.0x
|
1.8x
|
11.9x
|
395.8 M
|
204.8 M
|
12.9%
|
75.7%
|
-0.9
|
—
|
92.5%
|
